PAUL DAVANZO: Open Payments
NPI 1710749403 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,418 in 46 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $374 · 2025 $1,418
Food & beverage: $1,418
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $323 |
| E.R. Squibb & Sons, L.L.C. | 6 | $217 |
| Corium, LLC | 8 | $195 |
| Janssen Pharmaceuticals, Inc | 3 | $189 |
| Otsuka America Pharmaceutical, Inc. | 5 | $111 |
| ABBVIE INC. | 5 | $109 |
| Lundbeck LLC | 3 | $77 |
| Bausch Health US, LLC | 3 | $60 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Neos Therapeutics, LP | 1 | $31 |
Products named: CAPLYTA, COBENFY, Azstarys, SPRAVATO, REXULTI, VRAYLAR, APLENZIN, Qelbree.
Industry payments across NY — which companies pay providers there.
